# Qulipta - (10, 30 and 60 mg ; Tablet)

| | | | |
|---|---|---|---|
| **Generic Name** | Atogepant | **Innovator** | Abbvie |
| **Dosage** | 10, 30 and 60 mg ; Tablet | **Branded US Sales** | Less Than $1000 mn |
| **Probable FTF** | Less Than 5 | **Known Para IV Filers** | More Than 5 |
| **Other ANDA developers** | Less Than 5 | **Tentative Approvals** | None |
| **Final Approvals** | None | **Generic Launches** | None |
| **Indication** | QULIPTA is a calcitonin gene-related peptide receptor antagonist indicated for the preventive treatment of episodic migraine in adults. | | |
| **Complexities** | Yes | | |

## Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.

## Executive Summary
Please Contact contact@researchdelta.com to get Detailed Information.

## Patent Status
Please Contact contact@researchdelta.com to get Detailed Information.

## Launch Timelines and Competition
Please Contact contact@researchdelta.com to get Detailed Information.

## Chronology Of Events
Please Contact contact@researchdelta.com to get Detailed Information.